EpiBone
Hyungjin Jung is a Research Scientist at EpiBone, Inc. since August 2020, specializing in the development of osteochondral allogenic tissue grafts and leading successful FDA submissions. Prior experience includes a role as Senior R&D Scientist at Collagen Matrix, Inc., where Hyungjin developed collagen-based products and devices under stringent regulatory frameworks. Hyungjin also served as a Research Associate at Case Western Reserve University for over eight years, contributing to various projects on cartilage regeneration and biomaterials, and has a strong publication record. Academic qualifications encompass a PhD in Mechanical Engineering from Case Western Reserve University, along with a Master's degree and Bachelor's degree in Mechanical Engineering from Yonsei University. Additionally, military service includes training as a Sergeant in the Republic of Korea Army.
This person is not in any offices
EpiBone
3 followers
EpiBone is a revolutionary bone reconstruction company that allows patients to “grow their own bone”. EpiBone’s pioneering technology utilizes a scan of the patient’s bone defect and the patient’s own stem cells to construct and cultivate a defect-specific autologous-like bone graft. EpiBone is strategically positioned to provide a superior bone graft that will provide exact defect repair, a simplified surgical procedure, improved bone formation and regeneration, and shorter recovery times, without the complications of foreign body implantation, to the over 900,000 patients who undergo bone-related surgeries each year.